Clinical Trial Update: Effect Of GW501516X On How The Heart Obtains And Uses Energy

View source ↗

Summary

This update reports termination of a GlaxoSmithKline trial evaluating GW501516 (Cardarine) and its effects on heart energy metabolism in dyslipidemia and heart …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Heart Failure

Drugs mentioned

• Cardarine (GW501516)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Dyslipidaemias, Heart Failure | Status: TERMINATED